The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients.
Pellicelli, A., Pace Palitti, V., Vignally, P., CECCHERINI SILBERSTEIN, F., Siciliano, M., Giannelli, V., et al. (2017). Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. LIVER INTERNATIONAL, 37(5), 653-661 [10.1111/liv.13288].
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study
CECCHERINI SILBERSTEIN, FRANCESCA;MESSINA, VALERIA;IZZI, ALESSANDRO;D'AMBROSIO, CLAUDIO;SACCO, ROBERTO;PERNO, CARLO FEDERICO;
2017-01-01
Abstract
The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
